Japan Firms Work To Keep Nation's Lead In Regenerative Medicine
This article was originally published in PharmAsia News
Executive SummaryJapan's leading role in research on regenerative medicine is showing research and development progress as well as attracting venture capital
You may also be interested in...
The last year of the run up to the full implementation of the MDR has been characterized by a flurry of new documents and measures, but industry is adamant that medtech is heading for a crisis that will impact industry and patients alike.
The Chinese government's plan to reduce tariffs it imposed on a slew of US exports is expected to have minimal impact on the overall medtech industry. See what Ralph Ives, AdvaMed's executive VP for global strategy, said about it here.